Latest news with #066
New Straits Times
8 hours ago
- Business
- New Straits Times
Palm oil snaps four-day rally on weaker rival soyoil and crude
JAKARTA: Malaysian palm oil futures snapped a four-session rally on Tuesday, weighed down by rival soyoil at the Dalian and Chicago markets and the fall of crude prices. The benchmark palm oil contract for September delivery on the Bursa Malaysia Derivatives Exchange lost RM84, or 2.04 per cent, to RM4,042 (US$950.39) a metric ton in early trade. Dalian's most-active soyoil contract fell 1.82 per cent, while its palm oil contract shed 1.9 per cent. Soyoil prices on the Chicago Board of Trade were down 1.05 per cent. Palm oil tracks price movements of rival edible oils, as it competes for a share of the global vegetable oils market. Oil prices tumbled to a more than one-week low as US President Donald Trump said a ceasefire has been agreed between Iran and Israel, relieving worries of supply disruption in the area. Weaker crude oil futures make palm a less attractive option for biodiesel feedstock. Indonesia exported 1.78 million metric tons of palm oil, including refined products, in April, down from 2.18 million tons a year earlier, data from the Indonesia Palm Oil Association (GAPKI) showed. India's soyoil imports in June are likely to fall by 18 per cent from a month ago to a four-month low, as congestion at a key port will lead to unloading vessels into July instead of June. The ringgit, palm's currency of trade, strengthened 0.93 per cent against the dollar, making the commodity more expensive for buyers holding foreign currencies. Palm oil may break support of RM4,066 per metric ton, and fall towards RM4,017, Reuters technical analyst Wang Tao said. Global shares rallied and the dollar extended declines after Trump said Iran and Israel had agreed to a ceasefire.
Yahoo
15-05-2025
- Business
- Yahoo
Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial ...
Release Date: May 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Moleculin Biotech Inc (NASDAQ:MBRX) has officially started the Phase 3 Miracle trial for Anamycin, with the first patient already treated and 38 sites selected worldwide. The European Medicines Agency has given complete sign-off for the trial in all nine EU countries, marking a significant milestone. The World Health Organization has recognized a new generic drug name for Anamycin, Naxorubicin, aiding in its future market positioning. Additional patent protection for Anamycin has been secured, extending its composition of matter protection into at least 2040. The company is progressing with WP 1,066, a lead statory inhibitor, which is showing promise in treating brain tumors and is in a new clinical trial at Northwestern University. Moleculin Biotech Inc (NASDAQ:MBRX) ended the quarter with $8 million in cash, which will only sustain operations into the third quarter of the year, necessitating a $15 million raise. The company faces potential delays in EU approval due to additional GLP preclinical data requested by the EMA. There are minor differences between the US and EU protocols for the Phase 3 trial, which could complicate the harmonization process. The company acknowledges that the development of an IV delivery for WP 1,066 could encounter speed bumps, potentially delaying progress. The durability of complete remission in the MB 106 trial is still developing, with some patients relapsing after significant periods. Warning! GuruFocus has detected 1 Warning Sign with MBRX. Q: Does the requirement for additional GLP preclinical data by the EMA affect the timeline for EU approval compared to the US? A: Walter Klimt, CEO: We don't believe it will negatively impact the timeline. The EMA requested additional GLP preclinical data, which we can produce. While this could theoretically delay the EU's progression to Part B, we plan to continue recruiting in the US and non-EU sites during this period. Thus, the trial should not slow down, and we expect to meet EU patient requirements without affecting the approval timeline. Q: How close is Emory University to developing an optimal formulation for WP 1,066? A: Walter Klimt, CEO: We are beyond the discovery phase and are now implementing a strategy for a new formulation suitable for IV delivery. We aim to have progress by the end of the year, although there could be unforeseen delays. We expect to provide updates before the year ends. Q: Is the $3.5 million a fair run rate for R&D for the rest of the year, or will it increase? A: Jonathan Foster, CFO: The R&D expenses will increase, especially as we move into 2026 and incur GLP and manufacturing expenses. Currently, we have enough drugs for Part A, but we will need to start manufacturing for Part B. Q: Do you need durability data for potential approval, or is the 35-day CR rate sufficient? A: Walter Klimt, CEO: Durability is not a primary endpoint for approval; it's a secondary objective. The FDA has indicated that the CR rate is the primary endpoint. While durability is interesting, our approval doesn't depend on it. We are confident in our CR rate, which is expected to be significantly higher than the control arm. Q: Could underlying factors like age and genetic mutations impact the results? A: Walter Klimt, CEO: We will stratify by age and genetic mutations, but our primary endpoint isn't dependent on these factors. Our phase two data shows we are agnostic to genetic mutations and prior therapies, including Vanita lacks failures. We welcome all patient types, including elderly and those with mutational abnormalities. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
The Star
08-05-2025
- The Star
US boy uses mother's phone to order 70K lollipops to share with his friends
Boxes of Dum-Dum lollipops outside of LaFavers's home on May 5, 2025, in Lexington, Kentucky. — Holly LaFavers via AP LEXINGTON, Kentucky: A Kentucky woman was in a sticky mess when she found stacks of boxes containing lollipops on her front doorstep. The surprise delivery was ordered by her young son while he played on her phone. Holly LaFavers says she tried stopping eight-year-old Liam's Amazon order for about 70,000 Dum-Dum suckers before the treats arrived but it was too late. Amazon had already delivered 22 cases to her home. 'He told me that he wanted to have a carnival, and he was ordering the Dum-Dums as prizes for his carnival,' LaFavers said. 'Again, he was being friendly, he was being kind to his friends.' The surprise got worse after a quick check of her bank account. She owed about US$4,000 (RM17,066) for the order. 'When I saw what the number was, I just about fainted,' LaFavers said. Then she found out that eight more cases from the order were unaccounted for, she said. After a trip to the post office, those cases were returned to sender, she said. Her efforts to get a refund took a bit more time but she got her money back. 'After a long day of working with the bank and talking to a few news stations Amazon called and they are refunding my money,' she said in a social media post. LaFavers said she was changing some settings on her phone to make sure there's never another surprise delivery at home. – AP
